Business
Highly positive data from WSD4000 studies
Futura Medical plc has announced highly positive results from two studies on WSD4000, a product aimed at improving female sexual function. The Home User Test, involving 228 women over four weeks, showed significant improvements, with 78% reporting better overall sexual function and 84% liking the product's sensory feel after four uses. A placebo-controlled study in 33 women demonstrated WSD4000's statistical superiority to placebo in key measures like arousal, sensation, and lubrication. These findings enhance confidence in WSD4000's commercial potential, with the company planning to commence a pivotal clinical study by the end of 2026, subject to funding, and anticipating a market launch from early 2028. Disclaimer*
About this update from Futura Medical Plc
30 June 2026 Futura Medical plc ("Futura", "the Group" or the "Company") Highly positive data from WSD4000 studies Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to report the results from two studies on WSD4000: the Home User Test ('HUT') and the Placebo (Sham) Controlled Study. The positive results from both studies enhance the Company's belief in the commercial potential for WSD4000 and demonstrate that WSD4000 is superior to placebo (sham) thereby enabling it to proceed with the clinical study with high confidence of success. The Company expects to commence the clinical study by the end of 2026, subject to additional funding. Home User Test results summary WSD4000 was evaluated in 228 pre-, peri or post-menopausal women over a 4-week period. The results demonstrated that WSD4000 markedly improved sexual function from using the product. 78% of women reported a general improvement in all or most aspects of sex. 78% reported a more satisfying experience and 75% noticed having some increase in interest in having sex; 81% noticed an improvement to their overall sexual function. Overall, 68% of women rated the product 4 or 5 stars. 77% of participants had improved sexual experience after one use which increased to 84% after four uses. More specifically, after four uses: · 83% of women experienced improved lubrication (wetness) · 82% experienced improved genital sensation · 75% experienced improved arousal · 71% experienced faster arousal · 66% experienced greater ability to achieve orgasm · 61% experienced greater intensity of orgasm · 58% experienced less pain and discomfort during sex The study also showed that, in general, the product was well tolerated, with only 18% of women experiencing a transient unpleasant sensory effect but many of those still wished to continue to use the product. The sensory effect described as unpleasant in some subjects can be mitigated when commercialised by clear consumer explanation highlighting that this is part of the mode of action of the product Th...
View stock analysis, news, and events for Futura Medical Plc